Naslov
GM3 and CD15s highly expressing breast cancer stem cells are sensitive to novel thieno[2, 3- b]pyridine anticancer compound treatment

Autori
Mastelić, Angela ; Marijan, Sandra ; Markotić, Anita ; Režić- Mužinić, Nikolina ; Vuica-Ross, Milena ; Benzon Benjamin ; Barker, David ; Reynisson, Johannes ; Čikeš- Čulić, Vedrana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Proceedings of the Second Adriatic Symposium on Biophysical Approaches in Biomedical Studies : book of abstracts / Raguž, Marija ; Kalyanaraman, Balaraman ; Sarna, Tadeusz - Split : Medicinski fakultet Sveučilišta u Splitu, 2017, 65-65

ISBN
978-953-7524-22-7

Skup
Second Adriatic Symposium on Biophysical Approaches in Biomedical Studies

Mjesto i datum
Split, Hrvatska, 24.09.2017. - 28.09.2017

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
breast cancer ; cancer stem cells ; GM3 ; CD15s

Sažetak
Small subpopulation of cancer stem cells (characterized by CD44+CD24− phenotype) expresses GM3(NeuAc) and CD15s glycoconjugates. Acidic glycosphingolipid GM3(NeuAc), containing neuraminic acid substituted with acetyl residue, is known to inhibit tyrosine kinase associated with fibroblast growth factor receptor. CD15s glycoconjugate is the major ligand of endothelial (E) selectin, responsible for cancer cell metastasizing. We performed preliminary studies of viability, and GM3(NeuAc) and CD15s expression after treatment of MDA-MB-231 triple-negative breast cancer cells with a newly developed thienopyridine anticancer compound (1). The MTT assay was used for the cellular metabolic activity determination. Cells expressing highly GM3(NeuAc) and CD15s were analysed for their CD44+CD24- subpopulation percentage, and GM3(NeuAc) and CD15s median fluorescence intensity in CD44+CD24- gate using flow cytometry. The percentages of highly expressing GM3(NeuAc) and CD15s cancer stem cells were lower, and their GM3(NeuAc) median fluorescence intensity was higher after treatment with compound 1 in comparison to non-treated cells. There was no difference in CD15s expression after treatment with the same compound. Knowing the inhibitory role of GM3(NeuAc) in fibroblast growth factor signal transduction, these findings render compound 1 potentially useful for triple- negative breast cancer treatment.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA